ACE-031: A Literature Course on What the Studies Report

How this course works

This course walks through the indexed literature on ACE-031 in six modules: what the compound is, how its mechanism is described, what individual studies measured and reported, what adverse events appeared in publications, what pharmacokinetic information exists, and how the compound sits in the regulatory landscape. Each module closes with an explicit statement of where the evidence runs out. Nothing here is a protocol, a comparison of products, or an endorsement of use. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision or medical question.

Module 1: What ACE-031 Is and How It Has Been Studied

Definition and class

Across the published record, ACE-031 is described as a soluble form of the activin type IIB receptor (ActRIIB) — a recombinant fusion protein rather than a short synthetic peptide. The 2013 clinical report titled it a "muscle regulator" and characterised it as a soluble activin receptor type IIB construct given by subcutaneous injection in healthy volunteers. Animal work published in 2025 and 2026 used the same descriptor, calling ACE-031 "a soluble activin type IIB receptor" in studies of muscle mass and strength in the common marmoset. A separate clinical paper labelled it, in its title, a myostatin inhibitor tested in ambulatory boys with Duchenne muscular dystrophy.

Origin and study settings

The compound entered the literature as an investigational biologic developed for muscle-related indications. Two human studies dominate the clinical record: a single ascending-dose study conducted in healthy postmenopausal women, published in Muscle & Nerve in 2013 (PMID 23169607), and a randomised, placebo-controlled trial in ambulatory boys with Duchenne muscular dystrophy (DMD), published in the same journal in 2017 (PMID 27462804). Non-human primate work appeared much later: a bioRxiv preprint in 2025 reported that ACE-031 increased muscle mass and strength in common marmosets, with a peer-reviewed version in PLoS One in 2026 (PMID 41686840).

Forms encountered outside research settings

ACE-031 also appears in the analytical and forensic literature. A 2025 paper in Drug Testing and Analysis described gel electrophoretic detection of black-market ACE-031 — that is, methods work aimed at identifying material circulating outside regulated channels. Its existence in that literature reflects that unregulated preparations sold under the ACE-031 name are an analytical problem researchers have written about, not an approved dosage form.

Limits of the evidence in Module 1

The indexed record is small. There is no large-scale clinical programme, no long-term human cohort, and no head-to-head comparison with other ActRIIB-directed molecules in the verified literature reviewed here. Descriptions of formulation, concentration and purity for material sold under the ACE-031 name outside research settings are not established by these papers.

Module 2: Mechanism as Described in the Literature

The mechanistic framing is consistent across sources. ACE-031 is presented as a decoy or soluble receptor: the extracellular, ligand-binding portion of ActRIIB is produced as a circulating protein so that it can bind ligands that would otherwise engage the membrane-bound receptor. The 2013 clinical paper introduced the molecule in exactly these terms, as a soluble activin receptor type IIB acting as a muscle regulator, and the 2017 DMD trial titled it a myostatin inhibitor.

Myostatin (also called GDF-8) is a member of the TGF-β superfamily that signals through ActRIIB and restrains skeletal muscle growth. The rationale stated in the clinical literature is that intercepting such ligands with a soluble receptor reduces that restraint. Researchers in the marmoset studies applied the same logic to a non-human primate model, testing whether a soluble activin type IIB receptor would change muscle mass and strength.

Why mechanism and outcome are not the same claim

A described mechanism is a hypothesis about how a molecule works; it is not evidence that any particular clinical outcome follows. ActRIIB is engaged by more than one ligand, and a soluble receptor is not selective for myostatin alone. That biology is the most common explanation offered in the literature for why effects beyond skeletal muscle were observed in human studies — a point that becomes concrete in Module 4.

Limits of the evidence in Module 2

None of the verified human papers reviewed here established, in humans, which specific ligand interactions drove which observed changes. Signalling-pathway detail, receptor occupancy and tissue-level selectivity are not resolved by the clinical reports summarised in this course.

Module 3: Reported Outcomes by Study

Healthy volunteers, single ascending dose (2013)

The study was a randomised, placebo-controlled single ascending-dose design conducted in healthy postmenopausal women, in which single subcutaneous doses of ACE-031 were administered across an ascending range and body-composition and muscle measures were followed after that single exposure (PMID 23169607). Researchers reported dose-related increases in lean body mass and in thigh muscle volume alongside reductions in fat mass after single subcutaneous administration (PMID 23169607). Because this was a single-dose study in a healthy population, it measured short-term biological response rather than clinical benefit.

Ambulatory boys with Duchenne muscular dystrophy (2017)

The randomised, placebo-controlled trial administered subcutaneous ACE-031 to ambulatory boys with DMD and used walking capacity as its principal functional endpoint, with body composition among the exploratory measures (PMID 27462804). Dosing was stopped before the planned course was complete because of non-muscle adverse findings, and the researchers reported that the trial therefore did not demonstrate a statistically significant functional benefit on the walking endpoint (PMID 27462804). Directional changes in lean and fat mass consistent with the healthy-volunteer data were described, but the truncated exposure limits what those measures can support (PMID 27462804).

Common marmoset (2025 preprint; 2026 journal article)

The non-human primate work reported that ACE-031, a soluble activin type IIB receptor, increased muscle mass and strength in the common marmoset (Callithrix jacchus) (PMID 41256654). The peer-reviewed version published in PLoS One reported the same direction of effect on muscle mass and strength in that species (PMID 41686840). Animal findings describe what happened in marmosets under study conditions; they do not transfer to humans.

Analytical literature (2025)

The 2025 Drug Testing and Analysis paper was methodological rather than outcome-based: researchers described a gel electrophoretic approach for detecting ACE-031 in black-market material (PMID 40312924). It contributes to identity testing and doping-control analysis, not to efficacy or safety evidence.

Limits of the evidence in Module 3

Sample sizes were small, human exposure was short, and the one trial in a disease population ended prematurely. Increases in a body-composition measurement are not the same as improved strength, function, mobility or survival, and the published human record does not close that gap. No study in this set examined athletic performance, recomposition in healthy men, or older adults with sarcopenia.

Module 4: ACE-031 Side Effects: What Studies Report

Adverse events are the reason the clinical record on ACE-031 is short. In the randomised, placebo-controlled DMD trial, researchers reported bleeding-related and vascular findings — epistaxis (nosebleeds), gum bleeding and telangiectasias (small dilated blood vessels) — and dosing was discontinued early because of these non-muscle safety concerns (PMID 27462804). That decision, described in the publication itself, is the single most consequential safety observation in the ACE-031 literature (PMID 27462804).

In the earlier single ascending-dose study, researchers reported that single subcutaneous doses were generally well tolerated in healthy postmenopausal women over the follow-up period studied (PMID 23169607). A single exposure in healthy adults, however, is a weak test of the repeat-dose events later seen in the DMD population (PMID 27462804).

A separate, non-clinical consideration is product identity. The 2025 analytical paper exists because material sold as ACE-031 circulates through black-market channels, and researchers developed electrophoretic methods specifically to detect it in those preparations (PMID 40312924). Unverified material introduces uncertainties — identity, concentration, contamination — that clinical-trial safety data cannot speak to at all.

Limits of the evidence in Module 4

There is no long-term human safety dataset for ACE-031 in the verified literature: no multi-year follow-up, no data in older adults, none in pregnancy, and none on interactions with other medicines. Because dosing in the DMD trial was halted, the full adverse-event profile of a completed treatment course was never characterised (PMID 27462804). Absence of a reported event in a small, short study is not evidence that the event does not occur.

Module 5: Pharmacokinetics Where Data Exist

The most relevant pharmacokinetic source is the single ascending-dose study, which was designed around subcutaneous administration in healthy postmenopausal women and followed responses after one dose across an ascending dose range (PMID 23169607). Two structural features frame how that literature reads. First, ACE-031 is a protein and was given by injection in the human studies rather than orally (PMID 23169607). Second, single-dose designs of this kind are used precisely because Fc-containing fusion proteins persist in circulation long enough that a single administration can be followed for weeks.

The DMD trial used repeated subcutaneous administration in a paediatric population, so exposure there was cumulative rather than single-dose, and early discontinuation shortened the observation window for repeat-dose exposure (PMID 27462804). The marmoset publications add a non-human primate exposure setting in which increases in muscle mass and strength were reported (PMID 41686840).

Limits of the evidence in Module 5

Detailed human parameters — clearance, volume of distribution, accumulation with repeat dosing, immunogenicity and its effect on exposure, and the influence of body weight or renal function — are not established by the verified papers summarised here. Nothing in this record supports a statement about how long any effect persists in an individual, and no pharmacokinetic comparison across the human and animal studies has been published in this set.

Module 6: Regulatory Status, Stated Factually

Approved products

There is no ACE-031 product approved by the US Food and Drug Administration, the European Medicines Agency, or any comparable regulator. It appears in the literature as an investigational biologic: the two human studies in this course were clinical research, and the DMD trial reported that dosing was stopped early on safety grounds rather than progressing toward approval (PMID 27462804). Related soluble-receptor biology has continued to be studied in animals, including the marmoset work (PMID 41256654).

Research-use-only material

Material labelled "research use only" (RUO) is, by that label, not intended for human or veterinary use and has not been evaluated for safety, sterility, identity or potency as a medicine. RUO labelling is a statement about intended use in a laboratory, not a quality certification. The existence of analytical methods developed to detect ACE-031 in black-market preparations illustrates that material outside regulated supply chains is a documented phenomenon (PMID 40312924).

Compounding

In the United States, pharmacy compounding of a substance is constrained by sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. In general terms, a bulk drug substance used in compounding must be a component of an FDA-approved drug, be the subject of a USP or NF monograph, or appear on an FDA bulk-substances list. A biologic such as ACE-031, which has no approved product and no monograph in that framework, does not satisfy those statutory categories. Separately, biological products are licensed under the Public Health Service Act rather than compounded from bulk in routine practice.

Sport

Myostatin-directed agents are treated as performance-relevant substances in anti-doping analysis, which is the context in which detection methods for black-market ACE-031 were published (PMID 40312924). Athletes subject to testing rules are governed by their own governing bodies' prohibited lists, which change over time.

Limits of the evidence in Module 6

Regulatory status differs by country and changes; the summary above is general background drawn from how the compound appears in the literature. This is general regulatory information and not legal advice.

What the studies did not test

The verified literature on ACE-031 leaves large areas untouched. It did not test:

• Healthy adults using it for body composition or performance. The healthy-volunteer study was a single-dose safety and biology study in postmenopausal women, not a training or performance study (PMID 23169607).
• Long-term dosing. The DMD trial's dosing ended early, so no completed repeat-dose course was characterised (PMID 27462804).
• Functional benefit. Researchers reported no statistically significant benefit on the trial's walking endpoint (PMID 27462804).
• Human translation of the primate findings. The marmoset reports describe muscle mass and strength in marmosets (PMID 41686840).
• Unregulated products. The analytical paper addressed detection of black-market material, not its safety (PMID 40312924).
• Combinations, interactions, populations. No verified study here examined co-administration with other agents, older adults, or use during pregnancy or breastfeeding.

Read as a whole, the ACE-031 literature is a short arc: a mechanistic idea, an early human signal on body-composition measures, a controlled trial in a disease population that was stopped for adverse findings, later animal work, and analytical interest in unregulated material. Understanding that arc — including its termination point — is the point of this course.

References

• A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers (Muscle & Nerve, 2013)
• Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial (Muscle & Nerve, 2017)
• ACE-031, a Soluble Activin Type IIB Receptor, Increases Muscle Mass and Strength in the Common Marmoset (Callithrix jacchus) (bioRxiv, 2025)
• ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus) (PLoS One, 2026)
• Gel Electrophoretic Detection of Black Market ACE-031 (Drug Testing and Analysis, 2025)